118958-80-8

Upstream product

• 75-52-5 nitromethane 
• 351-54-2 3-fluoro-p-anisaldehyde 

Downstream Products

• 951745-15-6 1-tert-butoxycarbonyl-4-(5-(3-fluoro-4-methoxyphenyl)-1-(4-methoxyphenyl)-1H-pyrazol-3-yl)piperidine 
• 118958-85-3 N-ethyl-N-propionyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-81-9 N-ethoxycarbonyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-84-2 N-methyl-N-propionyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-83-1 N-methyl-N-acetyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-82-0 N-acetyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-89-7 N,N-di-n.propyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-92-2 N-ethyl-N-n.propyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-91-1 N-methyl-N-n.propyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-88-6 N,N-diethyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 118958-90-0 N-ethyl-N-methyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 52569-08-1 [2-(3-fluoro-4-methoxyphenyl)ethyl](methyl)amine 
• 118958-86-4 N-ethyl-2-(3-fluoro-4-methoxyphenyl)ethylamine 
• 113676-36-1 2-(3-fluoro-4-hydroxyphenyl)ethylamine hydrobromide 

Relevant academic research and scientific papers

6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER

The present invention discloses 6,7-dihydro-5H-pyrido[2,3- c]pyridazine, 1,2,3,4-tetrahydroquinoline, 1H-indole, 3,4- dihydro-2H-1,4-benzoxazine, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H- pyrrolo[2,3-c]pyridazine, 5H,6H,7H,8H,9H-pyridazino[3,4-b]azepine derivatives and related compounds of formula (I) as Bcl-xL protein inhibitors for use as pro-apoptotic agents for treating cancer, autoimmune diseases or immune system diseases. Formula (I). The description discloses the preparation of exemplary compounds (e.g. pages 113 to 354 examples 1 to 221) as well as pharmacological studies with relevant data (e.g. pages 355 to 367; examples A to E; tables 1 to 5). Exemplary compounds are e.g. 2-{6-[(1,3-benzothiazol-2-yl) amino]-1,2,3,4-tetrahydroquinolin-1-yl}-1,3-thiazole-4-carboxylic acid (example 1) or e.g. 3-{1-[(adamantan-1-yl)methyl]-5- methyl-1H-pyrazol-4-yl}-6-{3-[(1,3-benzothiazol-2-yl)amino]-4- methyl-5H,6H,7H,8H-pyrido[2,3-c]pyridazin-8-yl]pyridine-2-carboxylic acid (example 24).

DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS

The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.

Iron-Mediated One-Pot Synthesis of 3,5-Diarylpyridines from β-Nitrostyrenes

An operationally simple and mild one-pot protocol for the synthesis of a variety of 3,5-diarylpyridines from β-nitrostyrenes was achieved by using elemental iron. This reaction proceeds via reduction of the nitro group, resulting in in situ imine formation followed by trimolecular condensation with concomitant debenzylative aromatization. By employing this method, a series of symmetrical and unsymmetrical 3,5-diarylpyridines were synthesized with good to excellent yields. In addition, this method was also utilized for the synthesis of Sch-21418, an anti-inflammatory agent on gram scale.

Urea derivative or pharmacologically acceptable salt thereof

To provide a compound having a formyl peptide receptor-like 1 (FPRL1) agonist effect. The present invention relates to a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. The present invention also relates to a pharmaceutical composition which comprises the compound represented by general formula (I) or the pharmacologically acceptable salt thereof, and pharmaceutical use thereof.

UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES

This invention relates to a pharmaceutical comprising, as an active ingredient, a ureide derivative represented by formula: or a pharmaceutically acceptable salt thereof. The ureide derivative or a pharmaceutically acceptable salt thereof according to the present invention is useful for relieving pain and treating or preventing neuropathic pain.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF

Compounds of general formula (I) wherein D, E, R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES

A heterocyclic inhibitor having the formula (I), with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role.

Synthesis of some fluorinated nitro-olefins

The synthesis of fluorinated nitro-olefins from fluorinated benzaldehydes by aldol condensation is described.